IMM-101 + folinic acid + fluorouracil + irinotecan + cetuximab

IMM-101 + folinic acid + fluorouracil + irinotecan + cetuximab is an experimental combination regimen for cancer treatment. - **IMM-101** is an immunotherapeutic agent comprising heat-killed *Mycobacterium obuense*, designed to stimulate innate and adaptive immune responses against cancer cells by enhancing dendritic cell maturation and promoting cytotoxic T lymphocyte activity[5][1]. - **Folinic acid (leucovorin)** is a reduced form of folic acid used to potentiate the activity of fluorouracil by stabilizing the binding of the drug to thymidylate synthase, intensifying its antineoplastic effect. - **Fluorouracil (5-FU)** is a pyrimidine analog that inhibits thymidylate synthase, thus blocking DNA synthesis in rapidly dividing cancer cells. - **Irinotecan** is a topoisomerase I inhibitor that induces DNA strand breaks, leading to cell death. - **Cetuximab** is a recombinant chimeric monoclonal antibody targeting **epidermal growth factor receptor (EGFR)**, blocking EGFR-dependent cell signaling and inhibiting tumor cell proliferation[2][4][6]. The combination is investigational; each component is used for colorectal cancer and other solid tumors, with cetuximab indicated for K-Ras wild-type, EGFR-expressing metastatic colorectal cancer in combination with FOLFIRI (folinic acid, fluorouracil, irinotecan) or as monotherapy[6]. IMM-101 has primarily been studied in pancreatic cancer and melanoma, often with gemcitabine or checkpoint inhibitors, but its use with classical FOLFIRI + cetuximab chemotherapy is unestablished and experimental.

Other names

cetuximab + folinic acid + fluorouracil + irinotecan + IMM-101